Dr. Cederquist received her Bachelor's degree in Biology from Syracuse University prior to receiving her PhD in Biochemistry/Cell and Molecular Biology from Boston University School of Medicine in May of 2017. Her PhD studies focused on understanding the role of GPS2, a transcriptional cofactor, in regulating adipose tissue function and inflammation. These studies led to the novel discovery that AKT is regulated by non-proteolytic ubiquitination. Dr. Cederquist was funded by an NIH/NIDDK F31 predoctoral fellowship and received numerous awards during her graduate studies. Upon joining the Kahn lab in August of 2017 for her postdoctoral training, Dr. Cederquist has begun studying how metabolites produced or altered by gut microbiota can enhance or abrogate the insulin signaling pathway in metabolically active tissues.